Inna P. Gladysheva, PhD

Inna P. Gladysheva, PhD portrait
    • Primary Address
    • Office
    • University of Arizona College of Medicine - Phoenix
    • 475 North 5th Street, Suite E820
    • Phoenix, AZ, United States 85004



  • Postdoctoral Research Fellowship 2004, Cardiovascular Biology and Diseases, School of Public Health, Harvard University
  • Research Fellowship 2001, Targeted Drug Delivery, Moscow State University
  • PhD 1994, Biokinetic and Catalyze, Moscow State University
  • MS 1989, Chemistry, Lomonosov Moscow State University


Inna P Gladysheva, Ph.D., is a Professor of Medicine and Clinical Translational Science at the University of Arizona, College of Medicine-Phoenix (UA-COM-P) and a member of the Translational Cardiovascular Research Center. Dr. Gladysheva earned a master's degree in chemistry and Ph.D. in enzyme kinetics and biochemistry from Lomonosov Moscow State University, Russia, and completed a research fellowship in targeted drug delivery at Lomonosov Moscow State University and in cardiovascular biology and diseases at Harvard University's School of Public Health, Boston, MA. Prior to joining the UA COM-P, she was an Associate Professor of Medicine at the Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, and an Assistant Professor of Medicine at the Medical College of Georgia, Augusta, GA. Dr. Gladysheva translational research, which AHA and NIH funded, focuses on the molecular and pathophysiologic mechanisms of cardiomyopathy, heart failure, and concurrent complications to delay or prevent the transition from cardiac dysfunction (cardiomyopathies) to symptomatic HFrEF. Specifically, she is interested in proteases and hormones as potential diagnostic and therapeutic targets, and not pharmacological approaches (lifestyle choices) to modulate the progression of cardiomyopathy and the development of edema/congestion that signifies heart failure. Dr. Gladyshev has successfully contributed to multiple research projects on regulating uncontrolled proteolysis in cardiovascular disorders associated with thrombosis, cardiomyopathies, and HFrEF.